Tiemann Investment Advisors LLC Sells 208 Shares of Pfizer, Inc. (NYSE:PFE)

Tiemann Investment Advisors LLC cut its stake in shares of Pfizer, Inc. (NYSE:PFE) by 1.3% during the first quarter, according to its most recent filing with the SEC. The fund owned 16,228 shares of the biopharmaceutical company’s stock after selling 208 shares during the period. Tiemann Investment Advisors LLC’s holdings in Pfizer were worth $555,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Asset Planning Services Ltd. boosted its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the last quarter. Orrstown Financial Services Inc. boosted its stake in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the last quarter. Cable Hill Partners LLC raised its position in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares during the period. D Orazio & Associates Inc. raised its position in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares during the period. Finally, Acropolis Investment Management LLC raised its position in shares of Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 69.94% of the company’s stock.

Pfizer, Inc. (NYSE:PFE) opened at 32.67 on Friday. The company’s 50-day moving average price is $33.30 and its 200 day moving average price is $33.38. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.38. The company has a market capitalization of $194.30 billion, a price-to-earnings ratio of 23.90 and a beta of 1.00.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.64 EPS. On average, equities analysts expect that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.92%. Pfizer’s dividend payout ratio is presently 94.12%.

TRADEMARK VIOLATION NOTICE: This article was originally reported by BBNS and is owned by of BBNS. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://baseballnewssource.com/markets/tiemann-investment-advisors-llc-lowers-position-in-pfizer-inc-nysepfe-updated/1408213.html.

PFE has been the topic of a number of research reports. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets raised Pfizer from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and set a $38.00 target price on shares of Pfizer in a research report on Monday, July 31st. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Finally, Barclays PLC reaffirmed a “buy” rating and set a $38.00 target price on shares of Pfizer in a research report on Wednesday, May 3rd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $37.61.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.